The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
Spinal Muscular Atrophy (SMA) is monogenic motoneuron disease caused by low levels of the Survival of Motoneuron protein (SMN). Recently, two different drugs were approved for the treatment of the disease. The antisense oligonucleotide Nusinersen/Spinraza® and the gene replacement therapy Onasemnoge...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2020-02-01
|
| Schriftenreihe: | Frontiers in Neurology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/article/10.3389/fneur.2020.00045/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|